Global /United States /Healthcare /Drug Manufacturers - Specialty & Generic /CURX

Curanex Pharmaceuticals Inc.

CURX

• NASDAQ: CURX • Delayed

8.60USD 5%

As of 17 June 2026, Curanex Pharmaceuticals Inc. has a market cap of $9.5M USD, ranking #41841 globally and #5388 in the United States. It ranks #3706 in the Healthcare sector, and #252 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

41841

Country Rank

5388

Sector Rank

3706

Industry Rank

252

Key Stats

Market Cap

$9.5MUSD

Enterprise Value

$235.69MUSD

Net Income (TTM)

-$435.03KUSD

PB Ratio

770.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Jun Liu open_in_new

Founded

2018

IPO

26 Aug 2025

Website

curanexpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
5%	19%	12%	-25%	-18%	1.5%	-91%	-91%	-91%

News

CURX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CURX Curanex Pharmaceuticals Inc ISIN: US23126K1060 Shares Out.: Shares Outstanding: 28.365M¹ Shares Float: 8.72M² TV: TradingView: NASDAQ: CURX SA: Stock Analysis: NASDAQ: CURX YF: Yahoo Finance: CURX GF: Google Finance: NASDAQ: CURX NQ: NASDAQ: CURX BA: Barron's: CURX MS: Morningstar: XNAS: CURX	8.60 USD	TV: TradingView: NASDAQ: CURX SA: Stock Analysis: NASDAQ: CURX YF: Yahoo Finance: CURX GF: Google Finance: NASDAQ: CURX NQ: NASDAQ: CURX BA: Barron's: CURX MS: Morningstar: XNAS: CURX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Curanex Pharmaceuticals Inc.

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United States)

Name	Market Cap (USD) diff.	PE	Country
Revolution Medicines, Inc. NASDAQ: RVMD	$29.56B 311K%	-	United States
Indivior PLC LSE: INDV	$2.07B 1.54B GBP 22K%	-	United States
BellRing Brands, Inc. NYSE: BRBR	$2.06B 22K%	12.1	United States
Endo, Inc. OTCMKTS: NDOI	$1.8B 19K%	0.4	United States
Dynavax Technologies Corp. NASDAQ: DVAX	$1.76B 18K%	-	United States
ArriVent BioPharma, Inc. NASDAQ: AVBP	$1.33B 14K%	-	United States

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$37.36B 108.92B ILS 393K%	24.2	Israel
Zhejiang NHU Company Ltd. SHE: 002001	$15.88B 107.34B CNY 167K%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.26B 1.06T INR 118K%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.15B 1.05T INR 117K%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.12B 61.6B CNY 96K%	80.6	China
ABIVAX Société Anonyme EPA: ABVX	$8.79B 7.57B EUR 92K%	-	France

chevron_leftBack